- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.03. | EXTRAWELL PHAR (00858): POLL RESULTS OF THE SPECIAL GENERAL MEETING HELD ON 28 MARCH 2025 | - | HKEx | ||
| EXTRAWELL PHARMACEUTICAL Aktie jetzt für 0€ handeln | |||||
| 13.03. | EXTRAWELL PHAR (00858): SUPPLEMENTAL ANNOUNCEMENT, PROPOSED APPOINTMENT OF AUDITOR, NOTICE OF SPECIAL GENERAL MEETING | - | HKEx | ||
| 12.03. | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF CIRCULAR CONTAINING NOTICE OF SPECIAL ... | - | HKEx | ||
| 12.03. | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF CIRCULAR CONTAINING NOTICE OF SPECIAL ... | - | HKEx | ||
| 12.03. | EXTRAWELL PHAR (00858): NOTICE OF SPECIAL GENERAL MEETING | - | HKEx | ||
| 12.03. | EXTRAWELL PHAR (00858): FORM OF PROXY FOR SPECIAL GENERAL MEETING TO BE HELD ON FRIDAY, 28 MARCH 2025 AT 11:00 A.M. | - | HKEx | ||
| 12.03. | EXTRAWELL PHAR (00858): PROPOSED APPOINTMENT OF AUDITOR AND NOTICE OF SPECIAL GENERAL MEETING | - | HKEx | ||
| 07.03. | EXTRAWELL PHAR (00858): PROPOSED APPOINTMENT OF AUDITOR | 1 | HKEx | ||
| 17.12.24 | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF INTERIM REPORT 2024/25 | 1 | HKEx | ||
| 17.12.24 | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF INTERIM REPORT 2024/25 | - | HKEx | ||
| 17.12.24 | EXTRAWELL PHAR (00858): INTERIM REPORT 2024/25 | - | HKEx | ||
| 29.11.24 | EXTRAWELL PHAR (00858): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024 | 3 | HKEx | ||
| 19.11.24 | EXTRAWELL PHAR (00858): PROFIT ALERT | - | HKEx | ||
| 14.11.24 | EXTRAWELL PHAR (00858): DATE OF BOARD MEETING | 1 | HKEx |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IONIS PHARMACEUTICALS | 24,840 | -0,52 % | Ionis Aktie: Alles auf den Punkt gebracht | Ionis Pharmaceuticals verstärkt Zusammenarbeit mit Sobi und fördert weltweite Olezarsen-Vermarktung außerhalb der USA. Ionis Pharmaceuticals stärkt seine Position im Biotechnologiesektor durch strategische... ► Artikel lesen | |
| CSPC PHARMA | 0,602 | -2,21 % | Aktienmarkt: CSPC Pharmaceutical Group-Aktie kann sich nicht behaupten (0,6116 €) | Im Wertpapierhandel notiert das Wertpapier der CSPC Pharmaceutical Group derzeit leichter. Das Papier kostete zuletzt 0,61 Euro. Jahreschart der CSPC Pharmaceutical Group Ltd-Aktie, Stand 17.04.2025... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 12,810 | -1,23 % | ACADIA PHARMACEUTICALS INC - 8-K, Current Report | ||
| SELLAS LIFE SCIENCES | 1,180 | +3,51 % | SELLAS Life Sciences Group, Inc.: SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML | - 8.9 Months Median Overall Survival (mOS) in Patients with AML-Myelodysplasia-Related Changes (AML-MRC) and 8.8 mOS in All Relapsed or Refractory to Venetoclax-Based Regimens Patients; Surpassing... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 264,10 | -1,42 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed Chief Medical Officer | CONSHOHOCKEN, Pa., April 16, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 19,805 | -0,10 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Health Canada's Acceptance of AGAMREE New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals | CORAL GABLES, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing... ► Artikel lesen | |
| ENZON PHARMACEUTICALS | 0,063 | 0,00 % | ENZON PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| OPUS GENETICS | 0,651 | -1,36 % | Craig-Hallum sets $6 target for Opus Genetics stock, rates it a Buy | ||
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc. Announces First Shipment of Product from New Facility and Packaging Line | Northvale, New Jersey--(Newsfile Corp. - March 3, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| VIRACTA THERAPEUTICS | 0,008 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 10.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 10.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 10.02.2025ISIN NameES0105015012 LAR... ► Artikel lesen | |
| SAVARA | 2,620 | +3,15 % | Savara Inc.: Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences | Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced encore presentations of top-line data from the pivotal, Phase... ► Artikel lesen | |
| GALECTIN THERAPEUTICS | 1,180 | +1,72 % | Galectin Therapeutics Inc.: Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update | NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 1,400 | -2,10 % | Biodexa Pharmaceuticals PLC: Preliminary Results for the Year Ended 31 December 2024 | April 11, 2025 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company" or, together with its subsidiaries, the "Group") Preliminary Results for the Year Ended 31 December 2024 Biodexa Pharmaceuticals... ► Artikel lesen | |
| SCICLONE PHARMACEUTICALS | - | - | Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone | TOKYO, Feb 28, 2025 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company has entered into a license agreement granting the exclusive development and distribution rights for the fibroblast... ► Artikel lesen | |
| NOVABAY PHARMACEUTICALS | 0,080 | 0,00 % | NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results | EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and nine months ended September 30, 2024.
"Avenova sales through... ► Artikel lesen |
EXTRAWELL PHARMACEUTICAL HOLDINGS LTD gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EXTRAWELL PHARMACEUTICAL HOLDINGS LTD finden Sie auf Wallstreet Online.
